BofA analyst Geoff Meacham lowered the firm’s price target on Gossamer Bio (GOSS) to $7 from $15 and keeps a Buy rating on the shares. Despite a positive result for the phase 2 TORREY study in pulmonary arterial hypertension, or PAH, investors were "largely disappointed" by the efficacy data, which looks to be weaker than competitor Merck’s (MRK) sotatercept, sending shares down over 70% yesterday, noted Meacham. His lower target is based on a lower market opportunity, but he keeps a Buy rating since shares are trading below cash of $3 per share and he sees "a positive benefit / risk skew" for Gossamer, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GOSS:
- Gossamer Bio downgraded to Underweight from Neutral at JPMorgan
- Gossamer Bio downgraded to Equal Weight from Overweight at Barclays
- Gossamer Bio downgraded to Neutral from Outperform at SMBC Nikko
- Piper says ‘Street overreacted’ to Gossamer data, seralutinib still ‘promising’
- Gossamer Bio Tanks after Phase 2 Study Results in PAH